Skip to main navigation Skip to search Skip to main content

T2-high asthma phenotypes across lifespan

  • ALLIANCE Study Group
  • , N. Maison
  • , J. Omony
  • , S. Illi
  • , D. Thiele
  • , C. Skevaki
  • , A.-M. Dittrich
  • , T. Bahmer
  • , K.F. Rabe
  • , M. Weckmann
  • , C. Happle
  • , B. Schaub
  • , M. Meyer
  • , S. Foth
  • , E. Rietschel
  • , H. Renz
  • , G. Hansen
  • , M.V. Kopp
  • , E. von Mutius
  • , R. Grychtol
  • O. Fuchs, B. Roesler, N. Welchering, N. Kohistani-Greif, J. Kurz, K. Landgraf-Rauf, K. Laubhahn, C. Liebl, M. Ege, A. Hose, E. Zeitlmann, M. Berbig, C. Marzi, C. Schauberger, U. Zissler, I. Ricklefs, G. Diekmann, L. Liboschik, G. Voigt, L. Sultansei, G. Nissen, I.R. König, A.-M. Kirsten, F. Pedersen, H. Watz, B. Waschki, C. Herzmann, M. Abdo, H. Biller, K.I. Gaede, X. Bovermann, A. Steinmetz, B.L. Husstedt, C. Nitsche, V. Veith, M. Szewczyk, F. Brinkmann, A. Malik, N. Schwerk, C. Dopfer, M. Price, A.C. Jirmo, A. Habener, D.S. DeLuca, S. Gaedcke, B. Liu, M.-R. Calveron, S. Weber, T. Schildberg, S. van Koningsbruggen-Rietschel, M. Alcazar
  • Helmholtz Zentrum München German Research Center for Environmental Health
  • Ludwig-Maximilians-Universität München
  • Member of the German Center for Lung Research (DZL)
  • Universitätsklinikum Schleswig-Holstein Campus Lübeck
  • Member of the German Center for Lung Research (DZL)
  • Philipps-Universität Marburg
  • Somnomar Institut für Medizinische Forschung und Schlafmedizin
  • Medizinische Hochschule Hannover
  • Member of the German Center for Lung Research (DZL)
  • University Hospital Schleswig-Holstein
  • LungenClinic Grosshansdorf GmbH
  • Universität zu Köln
  • I.M. Sechenov First Moscow State Medical University
  • University Children's Hospital of Bern
  • Comprehensive Pneumology Center
  • German Center for Lung Research (DZL)
  • Technical University of Munich
  • German Zentrum of Lung Research (DZL)
  • Lung Research (DZL)
  • University Children's Hospital
  • Airway Research Center North (ARCN)
  • Pulmonary Research Institute at LungenClinic Grosshansdorf
  • Forschungszentrum Borstel - Zentrum für Medizin und Biowissenschaften
  • Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH)
  • Max-Planck-lnstitut für Kohlenforschung
  • University of Giessen Lung Center
  • The German Center for Lung Research
  • Uniklinikum Köln

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

Rationale In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children. Objectives To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages. Methods In the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited and followed for 2 years (1 year in adults). Extensive clinical characterisation (questionnaires, blood differential count, allergy testing, lung function and sputum induction (in adults)) was performed at baseline and follow-ups. Interleukin (IL)-4, IL-5 and IL-13 were measured after stimulation of whole blood with lipopolysaccharide (LPS) or anti-CD3/CD28. Measurements and main results Based on blood eosinophil counts and allergen-specific serum IgE antibodies, patients were categorised into four mutually exclusive phenotypes: “atopy-only”, “eosinophils-only”, “T2-high” (eosinophilia + atopy) and “T2-low” (neither eosinophilia nor atopy). The T2-high phenotype was found across all ages, even in very young children in whom it persisted to a large degree even after 2 years of follow-up. T2-high asthma in adults was associated with childhood onset, suggesting early origins of this asthma phenotype. In both children and adults, the T2-high phenotype was characterised by excessive production of specific IgE to allergens (p<0.0001) and, from school age onwards, by increased production of IL-5 after anti-CD3/CD28 stimulation of whole blood. Conclusions Using easily accessible biomarkers, patients with T2-high asthma can be identified across all ages delineating a distinct phenotype. These patients may benefit from therapy with biologicals even at a younger age.

Original languageEnglish
Article number2102288
JournalEuropean Respiratory Journal
Volume60
Issue number3
DOIs
StatePublished - 1 Sep 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'T2-high asthma phenotypes across lifespan'. Together they form a unique fingerprint.

Cite this